Quality Review
Meet the Q&PS Team
MedicASK Answers
MedicASK Answers Full List
Patient Safety Incident Report
Loss or theft of controlled substances
MedicASK
Files
Hypoglycemia and Stroke Bypass
Question# 1004
Upon reviewing the Stroke Bypass criteria, we noticed that a BGL under 3mmol would be a contraindication for a Stroke bypass.
Shouldn’t this be under 4mmol as any patient who is hypoglycemic could be perceived as having Stroke like symptoms.
Shouldn’t this be under 4mmol as any patient who is hypoglycemic could be perceived as having Stroke like symptoms.
Answer:
The two glucose thresholds serve different clinical purposes and are intentionally set at different levels. A blood glucose level (BGL) of less than 4.0 mmol/L is the treatment threshold for hypoglycemia and reflects the recognized point at which glucose should be corrected to prevent progression to more significant symptoms. This threshold is deliberately conservative and is designed to ensure that potentially harmful hypoglycemia is identified and treated early.
The stroke bypass exclusion threshold, however, is intended to address a different question: whether hypoglycemia is a plausible explanation for the patient's neurological deficits. While patients with BGLs between 3.0 and 4.0 mmol/L should still receive prompt glucose treatment, this range is not typically associated with the focal neurological findings that mimic stroke, such as aphasia, hemiparesis, facial droop, or gaze deviation. These neuroglycopenic symptoms are more commonly seen at lower glucose levels, generally below approximately 3.0 mmol/L.
As a result, a mildly hypoglycemic patient may require treatment, but their glucose level alone would not be expected to fully account for persistent stroke-like symptoms. In practical terms, a patient with a BGL of 3.5 mmol/L and a dense hemiparesis should receive glucose treatment because they are hypoglycemic, but they would not automatically be excluded from stroke bypass. If the neurological deficits persist, acute stroke remains a significant concern and timely access to definitive stroke care remains important.
Conversely, when glucose levels are below the bypass exclusion threshold, hypoglycemia becomes a more credible explanation for the presentation, making treatment and reassessment the appropriate next step before committing the patient to a stroke pathway.
Ultimately, the two thresholds work together rather than conflict with one another. The treatment threshold is intentionally set higher to ensure hypoglycemia is not missed, while the stroke bypass exclusion threshold is set lower to avoid attributing stroke symptoms to glucose levels that are unlikely to be the primary cause. This approach helps balance early correction of hypoglycemia with the need to avoid delays in time-sensitive stroke care.
As a last important point, if symptoms persist after correction of blood glucose level, the patient is not contraindicated for redirect/transport to the closest Designated Stroke Centre
The stroke bypass exclusion threshold, however, is intended to address a different question: whether hypoglycemia is a plausible explanation for the patient's neurological deficits. While patients with BGLs between 3.0 and 4.0 mmol/L should still receive prompt glucose treatment, this range is not typically associated with the focal neurological findings that mimic stroke, such as aphasia, hemiparesis, facial droop, or gaze deviation. These neuroglycopenic symptoms are more commonly seen at lower glucose levels, generally below approximately 3.0 mmol/L.
As a result, a mildly hypoglycemic patient may require treatment, but their glucose level alone would not be expected to fully account for persistent stroke-like symptoms. In practical terms, a patient with a BGL of 3.5 mmol/L and a dense hemiparesis should receive glucose treatment because they are hypoglycemic, but they would not automatically be excluded from stroke bypass. If the neurological deficits persist, acute stroke remains a significant concern and timely access to definitive stroke care remains important.
Conversely, when glucose levels are below the bypass exclusion threshold, hypoglycemia becomes a more credible explanation for the presentation, making treatment and reassessment the appropriate next step before committing the patient to a stroke pathway.
Ultimately, the two thresholds work together rather than conflict with one another. The treatment threshold is intentionally set higher to ensure hypoglycemia is not missed, while the stroke bypass exclusion threshold is set lower to avoid attributing stroke symptoms to glucose levels that are unlikely to be the primary cause. This approach helps balance early correction of hypoglycemia with the need to avoid delays in time-sensitive stroke care.
As a last important point, if symptoms persist after correction of blood glucose level, the patient is not contraindicated for redirect/transport to the closest Designated Stroke Centre